IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age65+
SponsorDuke University
About this trial
This randomized, double-blind, placebo-controlled clinical trial evaluates intravenous ferric derisomaltose in older adults with HFpEF and iron deficiency.
Eligibility criteria
Qualifiers
Ambulatory adults age >=65 years with HFpEF (EF >50%)
Hospitalized for HF in the past 12 months
TSAT <20%
Able to walk without assistance
Disqualifiers
Uncorrected severe valvular heart disease
Constrictive pericarditis
High output HF
Infiltrative cardiomyopathy
Trial design
Treatments tested in this trial
- Ferric derisomaltose
- Placebo (normal saline)
Treatment groups
300 Participants
are divided into 2 treatment groupsSponsors and collaborators
Duke University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute on Aging (NIA)
Collaborator
Kaiser Permanente
Collaborator
Source ClinicalTrials.gov